Biotech Distilled
Substack ↗ Subscribe
Subscribe Substack ↗ About

Home › Companies › CUE

Cue Biopharma

CUE Lead: Phase 2 8 Biotech Distilled articles ↓ 29 filings & releases ↓ Cash $17.4M (Jun 30, 2026) ↓ 8 verdicts ↓ 3 timing quotes ↓
ImmunologyOncology Protein

Market cap $136M 7.3M shares (10-Q, Aug 12, 2026) × $18.73 close Nov 6, 2026

Most recent annual filing: 2026-03-16

Catalyst timeline

4 trackedQuarter catalyst calendar →
  1. CUE-221 IND filing2H 2026CUE-221 IND filing, 2H 2026, material
  2. CUE-401 readout2H 2026/1H 2027CUE-401 readout, 2H 2026/1H 2027, material
  3. CUE-401 Ph1 startEnd of 2026CUE-401 Ph1 start, End of 2026, notable
  4. CUE-221 Ph2b start4Q 2026CUE-221 Ph2b start, 4Q 2026, notable

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (6 active programs)

Technology platforms

Immuno-STAT

Modular biologics platform designed to selectively engage and modulate disease-specific T cells for autoimmune, inflammatory, and oncology indications. Enables selective Treg induction/expansion, targeted cell depletion via anti-viral T cell redirection, and tumor-specific T cell activation.

Targets: TGF-β, IL-2, T cells, Tregs

Capital (as filed)

Cash
$17.4M cash and cash equivalents · Jun 30, 2026 (10-Q)
Operating cash flow
−$29.0M quarter Mar 31, 2026 → Jun 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$67.0M cash per the update of Sep 21, 2026 — the company's own words as read there, not the filed figure

Offering documents (3)

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 7, 2026.

Biotech Distilled coverage (8)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (8 calls)

Every verdict Biotech Distilled has published on Cue Biopharma, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. 2026-05-20 Watch Cue Biopharma, Inc. (CUE) — Scientific Deep Dive for CUE-221 and Pipeline Products CUE-221 biology is real and the H2 2026 Phase 2 CSU readout is a legitimate binary catalyst, but the equity is a going-concern story with a punishing change-of-control structure; track from the sidelines and re-evaluate after data.
  2. 2026-06-02 Speculative buy speculative UPDATE: Cue Biopharma (CUE) - The Horizon Crew Takes the Board The Horizon/AbbVie operator concentration on a five-person board is a real signal that upgrades the deal-prep probability, though the H2 2026 CSU binary and going-concern language are unchanged; position size capped at 1–2% of portfolio.
  3. 2026-07-10 Speculative buy speculative UPDATE: Cue Biopharma (CUE) - The $50M Vote of Confidence and the CSU Clock Cormorant-led $50M PIPE at $33.21 effectively neutralizes the going-concern gap and tightens the CSU readout to end of Q3 2026 (~11 weeks), materially raising the conditional probability on the constructive story while the binary science remains unchanged.
  4. 2026-07-13 Speculative buy speculative UPDATE: Cue Biopharma (CUE) - The CMO Chair Gets Filled, the PIPE Overhang Bites CMO hire completes the operator stack with ~11 weeks to the binary, while the 15.9% pullback back to the PIPE mark reflects dilution mechanics rather than any change in the fundamental setup.
  5. 2026-08-04 Speculative buy speculative UPDATE: Cue Biopharma (CUE) - The IND Nobody Noticed The food-allergy IND filing opens a US-jurisdiction clinical path that partially answers the China-data-acceptance risk, CSU readout guidance holds at end-of-Q3 for a third consecutive disclosure, and the 13.1% slide appears driven by resale-registration overhang rather than clinical news.
  6. 2026-08-15 Speculative buy speculative UPDATE: Cue Biopharma (CUE) - A $153 Million Loss That Isn't a Loss The $153M net loss is ~$110M of accounting artifact, the going-concern doubt is functionally resolved with management asserting twelve-month sufficiency, and a China manufacturing carve-out plus Driehaus crossing 5% further improve the regulatory and institutional picture ahead of the ~6-week CSU binary.
  7. 2026-08-22 Speculative buy speculative UPDATE: Cue Biopharma (CUE) - The CEO's 13D and the 30% Air Pocket The 29.9% drawdown is driven by PSU settlement sell-to-cover and a new S-3 shelf going effective — cap-table mechanics, not clinical news — while the CEO's skin in the game remains intact and the CSU binary is ~6 weeks away.
  8. 2026-09-22 Buy core UPDATE: Cue Biopharma (CUE) - The Coin Landed, and It Landed Off-Drug The Phase 2 CSU binary resolved favorably with a clean dose-response, blank safety table, and a 36-point off-drug gap at Week 28 that provides the first clinical evidence for the CD23 mechanism, substantially retiring clinical risk while FDA acceptance of the China dataset and the $215M Ascendant change-of-control acceleration remain as key structural overhangs.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (3 quotes from 3 filings)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (29)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Jul 9, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

21 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)